Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Acceleron Pharma (XLRN) Tops Q3 EPS by 10c
November 4, 2015 7:02 AM ESTAcceleron Pharma (NASDAQ: XLRN) reported Q3 EPS of ($0.36), $0.10 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $4.16 million versus the consensus estimate of $4.38 million.
For earnings history and earnings-related data on Acceleron Pharma (XLRN) click here.
... More